Pancreatitis and biliary obstructions. Why Choose the 12th Edition?
: Offers updated therapeutic algorithms for Inflammatory Bowel Disease (IBD), detailing the selection and sequencing of novel biologics, small molecules, and biosimilars. Core Section Breakdown
Reflecting recent global consensus changes, the hepatology sections thoroughly adopt the updated nomenclature for fatty liver diseases, transitioning completely to MASLD (formerly NAFLD) and MASH (formerly NASH). The text provides updated treatment algorithms for these metabolic conditions, alongside breakthroughs in the management of hepatitis B and C, cirrhosis complications, and patient selection for liver transplantation. 3. Precision Medicine in Gastrointestinal Oncology
Sleisenger and Fordtran's Gastrointestinal and Liver Disease s gastrointestinal and liver disease 12th edition
: Over 1,100 full-color illustrations and more than 20 procedural videos covering endoscopic techniques like balloon dilatation and stent placement.
The 12th edition introduces vital updates that reflect the rapidly changing landscape of gastroenterology and hepatology. The editors have systematically overhauled sections to incorporate precision medicine, advanced diagnostics, and novel therapeutic paradigms. 1. Precision Medicine and Genomics
: Hundreds of full-color endoscopic images, histological slides, and advanced radiological scans illustrate classic and rare disease presentations. Target Audience and Clinical Value Pancreatitis and biliary obstructions
The of Sleisenger and Fordtran's Gastrointestinal and Liver Disease
| | Key Update in the 12th Edition | | :--- | :--- | | Eosinophilic Esophagitis (EoE) | Updated diagnostic criteria (EoE Histology Scoring System); new therapies including budesonide oral suspension and dupilumab. | | Inflammatory Bowel Disease (IBD) | Comparative efficacy of advanced therapies (JAK inhibitors, anti-IL23, S1P modulators); role of intestinal ultrasound for monitoring. | | Pancreatic Cystic Lesions | Revised Sendai and Fukuoka guidelines; role of molecular markers (KRAS/GNAS mutations) in cyst fluid. | | Celiac Disease | Novel serologic markers (deamidated gliadin peptides); management of non-responsive celiac disease; potential for lanrazenotide. | | Colorectal Cancer Screening | USPSTF updated age to 45; role of multitarget stool DNA (Cologuard) and blood-based tests (Shield); post-polypectomy surveillance intervals. |
: Over 1,100 full-color illustrations and more than 20 procedural videos are included in the enhanced eBook version. Table of Contents (Summary of Major Parts) 4. Clinical Utility: Who Benefits Most?
Maintaining its hallmark consistent, templated format, the two-volume set is organized into major thematic sections for quick and efficient information retrieval.
Medical science has progressed rapidly since the previous edition. The 12th edition systematically integrates these breakthroughs across several major domains: The Gut Microbiome and Metagenomics
I can provide tailored recommendations based on your specific professional or academic needs.
The print text is accompanied by robust online access, featuring searchable text, updates on emerging clinical trials, and a library of procedural videos demonstrating advanced endoscopic techniques. 4. Clinical Utility: Who Benefits Most?